Result of Retail Offer

4 April 2024 - The Board of Evgen Pharma Plc is pleased to announce that the Retail Offer launched on 19 March 2023 has now closed, raising in aggregate £51,670 through the issuance of 5,167,000 Retail Offer Shares at a price of 1 pence each.

Accordingly, conditional on the passing of the Resolutions at the General Meeting and Admission, the Company has conditionally raised total gross proceeds of approximately £0.90 million in aggregate by way of the Fundraising.

Application has been made to the London Stock Exchange in connection with the admission of a total of 152,458,778 new Ordinary Shares to trading on AIM. This will comprise (i) 79,400,000 Placing Shares; (ii) 5,600,000 Subscription Shares (iii) 62,291,778 Initial Consideration Shares related to the Acquisition, and (iv) 5,167,000 Retail Offer Shares. The New Ordinary Shares, when issued, will rank pari passu with the existing Ordinary Shares then in issue.

Subject to, and conditional on, the Resolutions being passed at the General Meeting, Admission is expected to occur on 5 April 2024.

Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the announcement of the Fundraising made by the Company on 19 March 2024.

The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and the US as part of the continuing strategy to build the scientific data for the compound. Recently, Evgen completed an out-licensing transaction with Stalicla SA, a Swiss specialist company in neurodevelopmental disorders, commencing with autism spectrum disorder. The deal, if successful, will generate milestone payments of $160.5m and a double-digit royalty on sales.

For further information, please visit: www.evgen.com.

The Company's LEI is 213800NO3E6TSTQO8K20